Mostrar el registro sencillo del ítem
Characteristics and outcomes of people with gout hospitalized due to COVID-19: data from the COVID-19 Global Rheumatology Alliance Physician - reported registry
dc.contributor.author | Jatuworapruk, Kanon | pt_BR |
dc.contributor.author | Xavier, Ricardo Machado | pt_BR |
dc.contributor.author | Robinson, Philip C. | pt_BR |
dc.date.accessioned | 2023-10-03T03:35:43Z | pt_BR |
dc.date.issued | 2022 | pt_BR |
dc.identifier.issn | 2578-5745 | pt_BR |
dc.identifier.uri | http://hdl.handle.net/10183/265592 | pt_BR |
dc.description.abstract | Objective. To describe people with gout who were diagnosed with coronavirus disease 2019 (COVID-19) and hospitalized and to characterize their outcomes. Methods. Data on patients with gout hospitalized for COVID-19 between March 12, 2020, and October 25, 2021,were extracted from the COVID-19 Global Rheumatology Alliance registry. Descriptive statistics were used to describethe demographics, comorbidities, medication exposures, and COVID-19 outcomes including oxygenation or ventilation support and death. Results. One hundred sixty-three patients with gout who developed COVID-19 and were hospitalized were included. The mean age was 63 years, and 85% were male. The majority of the group lived in the Western Pacific Region (35%) and North America (18%). Nearly half (46%) had two or more comorbidities, with hypertension (56%), cardiovascular disease(28%), diabetes mellitus (26%), chronic kidney disease (25%), and obesity (23%) being the most common. Glucocorticoids and colchicine were used pre-COVID-19 in 11% and 12% of the cohort, respectively. Over two thirds (68%) ofthe cohort required supplemental oxygen or ventilatory support during hospitalization. COVID-19-related death wasreported in 16% of the overall cohort, with 73% of deaths documented in people with two or more comorbidities. Conclusion. This cohort of people with gout and COVID-19 who were hospitalized had high frequencies of ventilatory support and death. This suggests that patients with gout who were hospitalized for COVID-19 may be at risk of poor outcomes, perhaps related to known risk factors for poor outcomes, such as age and presence of comorbidity. | en |
dc.format.mimetype | application/pdf | pt_BR |
dc.language.iso | eng | pt_BR |
dc.relation.ispartof | ACR Open Rheumatology. Hoboken: American College of Rheumatology. Vol. 4, no. 11 (Nov. 2022), p. 948-953 | pt_BR |
dc.rights | Open Access | en |
dc.subject | COVID-19 | pt_BR |
dc.subject | Epidemiologia | pt_BR |
dc.subject | Gota | pt_BR |
dc.subject | Doenças reumáticas | pt_BR |
dc.subject | Reumatologia | pt_BR |
dc.subject | SARS-CoV-2 | pt_BR |
dc.subject | Hospitalização | pt_BR |
dc.subject | COVID-19 Global Rheumatology Alliance (GRA) | pt_BR |
dc.title | Characteristics and outcomes of people with gout hospitalized due to COVID-19: data from the COVID-19 Global Rheumatology Alliance Physician - reported registry | pt_BR |
dc.type | Artigo de periódico | pt_BR |
dc.identifier.nrb | 001175804 | pt_BR |
dc.type.origin | Estrangeiro | pt_BR |
Ficheros en el ítem
Este ítem está licenciado en la Creative Commons License
-
Artículos de Periódicos (39559)Ciencias de la Salud (10608)